TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M

Oncology Institute, Inc.

2023-Q3 EPS reported -$0.71 revenue$238,451,000

Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).
Net loss $17.4M ($0.19 diluted loss) vs $2.7M loss ($0.03 loss) prior year; Adjusted EBITDA loss $(5.3)M vs $(6.7)M.
Cash and investments $87.4M as of Sept 30, 2023.
Opened 70th clinic, added 5 physicians (total 112); signed full-risk capitated contract in South Florida effective Jan 1, 2024.
Reaffirmed full year 2023 guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Oncology Institute, Inc. reported three months ended September 30, 2023 results: revenue $82 million, net income Net loss of $17.4 million, EPS $(0.19). Guidance reaffirmed.

Period: three months ended September 30, 2023
Revenue: $82 million
Net income: Net loss of $17.4 million
EPS: $(0.19)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

new Chief Operating Officer • Signed full-risk capitated contract in South Florida, effective January 1, 2024 Third Quarter 2023 Financial Highlights • Consolidated revenue of $82 million, an increase of 26% compared to the prior year quarter • Gross profit of $16 million, an increase of 23% compared to the prior year quarter, and gross margin of 19.5%, a decrease

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.